Sanofi Drops Amgen UPC Case After Cholesterol Drug Deal
Europe's patent court has signed off on a joint request from Sanofi, Regeneron and Amgen to dismiss claims that Amgen was infringing on a patented antibody treatment for high cholesterol following...To view the full article, register now.
Already a subscriber? Click here to view full article